Targeted agent slows recurrent ovarian cancer
ASCO 2011: Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in progression-free survival when bevacizumab (Avastin) was added to chemotherapy, results of a multicenter...
View ArticleAvastin Boosts Survival in High-Risk Ovarian Ca
ASCO 2011: Adding an anti-angiogenic agent to chemotherapy appears to prolong life in women with high-risk ovarian cancer, a researcher said here.
View ArticlePromising Breast Cancer Treatment Averts 'Collateral Damage' to Healthy Cells
Doctors meeting this week at a major conference in Chicago believe they are on track to create a drug that would specifically target cancer cells, while largely leaving healthy cells undamaged. Gwen...
View ArticleNews from the 2012 ASCO Annual Meeting: Monday, June 4, 2012 (Dr. Sylvia Adams)
New studies highlighting the promise of individualized, precision medicine were released today at the 48th Annual Meeting of the American Society of Clinical Oncology.
View ArticleNews from the 2012 ASCO Annual Meeting: Monday, June 4, 2012 (Dr. Nicholas...
New studies highlighting findings that will lead to improvements in the patient experience and identifying potential risks for development of cancers in the future were released today at the 48th...
View ArticleNews from the 2012 ASCO Annual Meeting: Sunday, June 3
Findings from major clinical trials of prostate, breast, colorectal, brain cancers and lymphoma treatment were released today at the 48th Annual Meeting of the American Society of Clinical Oncology....
View ArticleASCO 2012 Meeting Highlights: News on brain tumors, lymphoma, breast,...
Bruce Roth, MD, of Siteman Cancer Center at Washington University in St. Louis, discusses news highlights from ASCO's 2012 Annual Meeting regarding new combinations of existing therapies and patients'...
View ArticleSABCS 2012: Neoadjuvant Chemo Benefits Young Women with Triple-Negative...
A review of nearly 9,000 breast cancer patients found young women under the age of 35 years were more likely to have a complete pathological response to neoadjuvant chemotherapy than older women. This...
View ArticleSABCS 2012: Outcomes Similar for 1 vs. 2 Years of Trastuzumab for...
Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical...
View ArticleSABCS 2012: ATLAS Results Support Extending Estrogen-Blocking Tamoxifen Therapy
Extending tamoxifen therapy from the standard five years to 10 years provided additional protection against breast cancer recurrence and an improvement in overall survival. These findings could have...
View ArticleSABCS 2012: Disparity of Care for Black Women With Breast Cancer
IMNG Medical News reporter Michele Sullivan interviews Dr. Dalliah Black on her report that black women with early breast cancer are less likely to be staged with sentinel lymph node biopsy -- and...
View ArticleASH 2012: Using HIV to Treat Cancer
A potentially groundbreaking procedure using a disable form of HIV to treat acute lymphoblastic leukemia was presented at the American Society of Hematology 2012 meeting.
View ArticleWorry, Fatigue and Chemo Brain
The cognitive condition commonly known as Chemo Brain begins before chemotherapy, according to a functional imaging study in breast cancer patients. Michele Sullivan interviews Bernadine Cimprich,...
View ArticleASCO 2013: An Update on Prostate Cancer Tx
Dr. David Quinn sits down with Selma Schimmel in The Group Room to discuss the prostate cancer data news at ASCO 2013.This interview was filmed at the American Society of Clinical Oncology Annual...
View ArticleProstate Cancer Screening in 2013
Chris Knight, MD, FACP, discusses PSA screening and radical prostatectomy at the American College of Physicians Internal Medicine 2013 Annual Scientific Meeting. More than 200 sessions are available...
View Article
More Pages to Explore .....